Financial Contrast: Incannex Healthcare (NASDAQ:IXHL) & Tvardi Therapeutics (NASDAQ:TVRD)

Incannex Healthcare (NASDAQ:IXHL – Get Free Report) and Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.

Institutional and Insider Ownership

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 9.1% of Incannex Healthcare shares are owned by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Incannex Healthcare and Tvardi Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Incannex Healthcare N/A -20.27% -19.15%
Tvardi Therapeutics N/A -179.87% -107.78%

Risk and Volatility

Incannex Healthcare has a beta of 7, meaning that its share price is 600% more volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500.

Earnings and Valuation

This table compares Incannex Healthcare and Tvardi Therapeutics”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Incannex Healthcare $90,000.00 259.37 -$19.30 million ($1.24) -1.50
Tvardi Therapeutics N/A N/A -$18.21 million ($2.68) -0.37

Tvardi Therapeutics has lower revenue, but higher earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Incannex Healthcare and Tvardi Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incannex Healthcare 2 0 1 0 1.67
Tvardi Therapeutics 1 0 6 1 2.88

Incannex Healthcare presently has a consensus price target of $18.00, indicating a potential upside of 867.74%. Tvardi Therapeutics has a consensus price target of $9.40, indicating a potential upside of 850.17%. Given Incannex Healthcare’s higher possible upside, research analysts clearly believe Incannex Healthcare is more favorable than Tvardi Therapeutics.

Summary

Incannex Healthcare beats Tvardi Therapeutics on 7 of the 13 factors compared between the two stocks.

About Incannex Healthcare

(Get Free Report)

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing investigational medicines, including cannabinoid-based combination therapies and psychedelic-assisted treatments. Its research focuses on conditions with significant unmet medical needs; its products are in development and are not established as approved treatments. The company’s pipeline has included IHL-42X, a combination of dronabinol and acetazolamide being studied for obstructive sleep apnea, as well as programs targeting inflammatory conditions and traumatic brain injury.

About Tvardi Therapeutics

(Get Free Report)

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and fibrotic diseases. The company’s research focuses on STAT3, a protein involved in processes that can contribute to tumor growth and fibrosis. Its lead drug candidate, TTI-101, is an oral small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. Tvardi is also advancing additional drug candidates based on its STAT3 research platform. Headquartered in The Woodlands, Texas, Tvardi is focused on research and clinical development; its investigational candidates are not established commercial products.

Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.